

Gideon M Blumenthal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3000433/publications.pdf>

Version: 2024-02-01

23
papers

2,002
citations

567281

15
h-index

642732

23
g-index

24
all docs

24
docs citations

24
times ranked

4280
citing authors

#	ARTICLE	IF	CITATIONS
1	Approvals in 2019: international review and a new agnostic molecular entity. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 130-131.	27.6	8
2	Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs. <i>Oncologist</i> , 2020, 25, 348-354.	3.7	6
3	A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 247-257.	2.8	13
4	Approvals in 2018: a histology-agnostic new molecular entity, novel end points and real-time review. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 139-141.	27.6	21
5	Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer. <i>PLoS ONE</i> , 2019, 14, e0212097.	2.5	6
6	A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics. <i>JAMA Oncology</i> , 2018, 4, 849.	7.1	220
7	Approvals in 2017: gene therapies and site-agnostic indications. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 127-128.	27.6	17
8	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. <i>Lancet Oncology</i> , The, 2018, 19, 229-239.	10.7	111
9	The FDA Oncology Center of Excellence and precision medicine. <i>Experimental Biology and Medicine</i> , 2018, 243, 308-312.	2.4	28
10	Special Considerations in Radiation Therapy Trials. , 2018, , .		0
11	Approvals in 2016: the march of the checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 131-132.	27.6	16
12	Real-world Data for Clinical Evidence Generation in Oncology. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	228
13	Setting the Record Straight on FDA Approvals in Oncology. <i>JAMA Internal Medicine</i> , 2017, 177, 1222.	5.1	1
14	Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies. <i>Oncologist</i> , 2017, 22, 762-767.	3.7	56
15	Treatment Beyond Progression With Immune Checkpoint Inhibitors—Known Unknowns. <i>JAMA Oncology</i> , 2017, 3, 1473.	7.1	26
16	Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 974-980.	3.7	64
17	Response Rate as an Approval End Point in Oncology. <i>JAMA Oncology</i> , 2016, 2, 780.	7.1	24
18	Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 1008-1014.	1.6	179

#	ARTICLE	IF	CITATIONS
19	A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors. <i>Oncotarget</i> , 2014, 5, 8161-8172.	1.8	31
20	Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer. <i>Obstetrics and Gynecology</i> , 2013, 121, 461-464.	2.4	4
21	PTEN loss in the continuum of common cancers, rare syndromes and mouse models. <i>Nature Reviews Cancer</i> , 2011, 11, 289-301.	28.4	682
22	Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. <i>Leukemia Research</i> , 2011, 35, 87-94.	0.8	19
23	PTEN hamartoma tumor syndromes. <i>European Journal of Human Genetics</i> , 2008, 16, 1289-1300.	2.8	240